Trospium Chloride Extended-Release Capsules — Class II drug recall D-0139-2024
Ongoing recall by Padagis US LLC, reported 2023-12-13, distributed nationwide. Failed Tablets/Capsules specifications; missing/broken/extra tablets within the capsules
| Recall number | D-0139-2024 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Padagis US LLC, Minneapolis, MN, United States |
| Recall initiated | 2023-11-01 |
| Classified | 2023-12-05 |
| Reported by FDA | 2023-12-13 |
| Distributed | Nationwide (US) |
| Quantity | 7,032 bottles |
| NDC | 00574-0118, 00574-0118-30 |
| Lot numbers | 231104, 231105, 231106 |
| Expiration dates | 2025-07-31 |
Product
Trospium Chloride Extended-Release Capsules, 60 mg, 30 Capsules per bottle, Rx Only, Manufactured By: Sidmak Laboratories (India) Pvt. Ltd. Plot No. 20, Pharmacity, Selaqui Industrial Area, Dehradun-248 197 Uttarakhand, India Distributed By: Padagis, Allegan, MI 49010. NDC: 0574-0118-30
Reason for recall
Failed Tablets/Capsules specifications; missing/broken/extra tablets within the capsules
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0139-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.